Phase 4 N=30 Duloxetine Treatment in Elderly With Dysthymia
Depression · Dysthymic Disorder
Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=18 Wellbutrin XL for Dysthymic Disorder
Dysthymic Disorder
Primary: Hamilton Depression Rating Scale, 24 Items (HDRS) — 14.4; 13.3 units on a scale — p=<.05
Phase 4 N=34 Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
Dysthymic Disorder
Primary: Hamilton-Depression Rating Scale (HDRS-24 Items) — 10.88; 16.41 units on a scale — p=0.10
Phase 4 N=249 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
Sleep Disorders · Obstructive Sleep Apnea · Major Depressive Disorder
Primary: Change From Baseline on Maintenance of Wakefulness Test (MWT) to Endpoint (12 Weeks or Last Observation After Baseline) — 2.6; 1.1 Minutes — p=0.3043
Phase 3 N=61 Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Treatment Responder — 9; 4 Participants
Phase 4 N=65 Duloxetine for Chronic Depression: a Double-blind Study
Dysthymic Disorder · Depressive Disorder NOS
Primary: Hamilton Depression Rating Scale (HDRS) - 24 Total Score — 5; 10 Scores on a scale — p=.003
Phase 4 N=59 Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Dysthymic Disorder · Dysthymia · Chronic Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HDRS24) — 14.63; 14.21 units on a scale — p=0.09
Phase 4 N=183 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
Depression · Generalized Anxiety Disorder · Panic Disorder
Primary: Change in Mental Health-related Quality of Life From Baseline to 24 Weeks — 8.87; 8.39 units on a scale — p=0.002
N/A N=63 Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
Opioid-use Disorder · Anxiety Disorders · Depressive Disorder
Primary: Change in Anxiety Symptoms as Assessed by Generalized Anxiety Disorder- Q-IV Scale — -1.8; -1.04; -2.47; -1.53 units on a scale — p=.755
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
Phase 4 N=54 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
Weight Gain
Primary: Change in Weight From Baseline to Endpoint. — -1.1; 5.9 Pounds
N/A N=304 Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder
Major Depressive Disorder · Posttraumatic Stress Disorder · Panic Disorder and Agoraphobia
Primary: PTSD Checklist for DSM-5 (PCL-5) — 48.0; 46.37; 42.44; 36.95 score on a scale
Phase 4 N=75 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
Schizophrenia
Primary: Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52 — 50.65; 58.71; 5.35; 5.96 units on a scale — p=0.8595
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
Phase 4 N=149 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD
Bipolar Disorder · Panic Disorder · Generalized Anxiety Disorder
Primary: Change From Baseline in the CGI-21 Anxiety — 4.9; 2.9; 3.4 score on a scale — p=<.05